STX Shield Therapeutics Plc

TIDMSTX

Shield Therapeutics PLC

09 August 2021

Shield Therapeutics plc

("Shield or the "Company" or the "Group")

AEGIS-CKD study results published in American Journal of Kidney Disease

Ferric maltol demonstrates statistically significant (16 weeks) and sustained (up to 52 weeks) increase in haemoglobin, compared to placebo, in subjects with chronic kidney disease (CKD) and iron deficiency

anaemia (ID)

London, UK, 9 August 2021: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru(R)/Accrufer(R) (ferric maltol), notes the recent on-line publication in the American Journal of Kidney Disease showing positive 16 week and long-term results from a study comparing the effectiveness of ferric maltol 30 mg bid with placebo over 16 weeks (2:1 randomization), and long-term up to 52 weeks. The primary endpoint was change from baseline in haemoglobin at week 16.

The double-blind randomised placebo-controlled Phase 3 study included adults with stage 3/4 CKD and mild to moderate iron-deficiency anaemia (IDA), who also had serum ferritin levels below 250 <MU>g/L and transferrin saturation below 25% or ferritin levels below 500 <MU>g/L and transferrin saturation below 15%. The paper concluded that the AEGIS-CKD trial shows that oral ferric maltol raises and sustains haemoglobin to provide iron for erythropoiesis in patients with eGFR as low as 30 mL/min/1.73 m2. Further, ferric maltol provides significant and sustained increases in iron storage indices, providing long-term control of IDA. In this population, ferric maltol was generally well tolerated, with a low rate of discontinuation due to adverse events. A drug such as ferric maltol that is able to replace and restore iron, that is orally administered, and that patients are able to tolerate will provide a clinically relevant treatment option for patients with moderate to severe CKD and anaemia due to iron deficiency

The publication can be found at https://pubmed.ncbi.nlm.nih.gov/34029682/

The lead author, Dr Nelson Kopyt stated: "Iron deficiency anaemia is a common problem that we must deal with in our CKD patients. With the data from this study we now have very good evidence that oral ferric maltol is well tolerated and results in a statistically significant and sustained increase in haemoglobin for the 52 weeks studied. This is very exciting news as we now have an iron preparation that can be administered orally with patient tolerability comparable to placebo."

For further information, please contact:

 
 Shield Therapeutics plc                                                +44 (0) 191 511 8500 
 Greg Madison (CEO) 
  Hans-Peter Rudolf, CFO 
 
 Peel Hunt LLP - Nominated Adviser & Joint 
  Broker                                                                +44 (0) 20 7148 8900 
 James Steel / Christopher Golden 
 
 finnCap Ltd - Joint Broker                                             +44 (0) 20 7220 0500 
 Geoff Nash / Alice Lane/ George Dollemore 
 
 Walbrook PR - Financial PR & IR Adviser                                +44 (0) 20 7933 8780 
 Paul McManus / Lianne Cawthorne/ Alice                             or shield@walbrookpr.com 
  Woodings 
 
 

About Shield

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru (R) /Accrufer (R) (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

Shield's lead product, Feraccru(R)/Accrufer(R), has been approved for use in the United States, European Union, UK, Switzerland and Australia and has exclusive IP rights until the mid-2030s. The Group is currently launching Accrufer(R) in the US. Feraccru(R) is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru(R)/Accrufer(R) in China, Hong Kong, Macau and Taiwan.

For more information, please visit www.shieldtherapeutics.com . Follow Shield on Twitter @ShieldTx

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAPFMITMTMMBBB

(END) Dow Jones Newswires

August 09, 2021 02:00 ET (06:00 GMT)

Shield Therapeutics (LSE:STX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Shield Therapeutics (LSE:STX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024